Vantage Consulting Group Inc / RPRX
Vantage Consulting Group Inc’s Royalty Pharma PLC Position
Does Vantage Consulting Group Inc own Royalty Pharma PLC (RPRX)? Not currently — the last reported position was 57.5K shares worth $2M in Q3 2023; the fund’s latest 13F (Q4 2025) no longer reports it.
Position Value
$2M
Q3 2023
Shares
57.5K
% of Portfolio
+1.05%
Quarters Held
12
position exited
Position History RPRX
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q3 2023 | 57.5K | $2M | +1.05% |
| Q2 2023 | 650.7K | $20M | +11.51% |
| Q1 2023 | 1.02M | $37M | +20.91% |
| Q4 2022 | 1.02M | $35M | +20.94% |
| Q3 2022 | 1.02M | $41M | +23.99% |
| Q2 2022 | 1.05M | $44M | +24.80% |
| Q1 2022 | 2.73M | $106M | +41.47% |
| Q4 2021 | 4.60M | $183M | +49.30% |
| Q3 2021 | 7.86M | $284M | +60.85% |
| Q2 2021 | 9.30M | $381M | +66.33% |
| Q1 2021 | 8.71M | $380M | +76.23% |
| Q4 2020 | 21.48M | $1.1B | +87.53% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Vantage Consulting Group Inc’s full portfolio or all institutional holders of RPRX.